Dwayne "The Rock" Johnson TRT: What Clinicians Should Tell Patients

What Has Dwayne Johnson Actually Said About TRT and Steroids?

Johnson's public statements are the only verified starting point. In a 2009 interview with Rolling Stone, he acknowledged using anabolic steroids at age 18 with a college football teammate, describing the experience as naive experimentation that he did not continue. He said, "We were just experimenting with it." That single admission is the one confirmed, attributed statement in the record.

Since then, journalists, fitness commentators, and social media analysts have speculated extensively about whether his physique at ages 45 to 52 reflects ongoing performance-enhancing drug use, including testosterone replacement therapy or recombinant human growth hormone (rhGH). Johnson has addressed these rumors with varying degrees of directness across interviews and Instagram posts, generally deflecting rather than confirming or denying current TRT use.

What Inference Looks Like vs. What Evidence Looks Like

No verified, sourced interview as of this writing confirms that Johnson currently uses prescription testosterone. Several widely shared articles cite "sources" or draw inference from physique assessments by sports medicine physicians who have never examined him. Clinicians should help patients understand the difference between a confirmed statement and a physique-based inference. The two are not equivalent, and treating them as equivalent undermines the patient's ability to evaluate health information critically.

Why the Ambiguity Matters Clinically

The ambiguity itself is clinically meaningful. Patients may arrive having already decided that Johnson "obviously" uses TRT, and they may use that belief to justify requesting testosterone without symptoms or documented deficiency. That reasoning pattern deserves respectful but direct pushback grounded in the diagnostic criteria covered below.

The Clinical Case for TRT: Who Actually Qualifies

Testosterone replacement therapy is a well-studied intervention for men with documented hypogonadism. The American Urological Association's 2018 clinical guideline defines hypogonadism as symptoms consistent with low testosterone combined with two separate morning serum testosterone measurements below 300 ng/dL, drawn on different days. The full guideline is available from the AUA.

Symptoms include reduced libido, erectile dysfunction, fatigue, decreased muscle mass, increased adiposity, depressed mood, and reduced bone mineral density. None of these symptoms alone is diagnostic, and all overlap with other conditions.

Prevalence Data

A cross-sectional analysis published in the International Journal of Clinical Practice by Mulligan et al. Estimated that 2.1 to 2.4 million U.S. Men carry a diagnosis of hypogonadism, with prevalence rising sharply after age 45. The study is indexed on PubMed. Age-related decline in serum testosterone averages approximately 1 to 2 percent per year after age 30, according to data from the Massachusetts Male Aging Study. See the MMAS data on PubMed.

What FDA-Approved TRT Actually Looks Like

FDA-approved testosterone formulations include intramuscular injections (testosterone cypionate, testosterone enanthate), transdermal gels (AndroGel, Testim, Fortesta), transdermal patches, buccal tablets, subcutaneous pellets, and a nasal gel (Natesto). Therapeutic doses for injectable testosterone cypionate typically range from 75 to 100 mg intramuscularly once weekly, titrated to maintain trough serum testosterone between 400 and 700 ng/dL. See the FDA prescribing information for testosterone cypionate.

That dose range is a fraction of the supraphysiologic doses associated with bodybuilding or physique competition, which may reach 500 to 1,000 mg per week or higher when combined with other anabolics.

Monitoring Requirements

Patients on TRT require periodic monitoring. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends checking hematocrit at baseline, at 3 to 6 months, and then annually, given the erythropoietic effect of testosterone. The guideline is available via the Endocrine Society. PSA and digital rectal exam follow current prostate cancer screening recommendations. Serum testosterone should be checked at 3 months and then every 6 to 12 months once stable.

Human Growth Hormone: A Separate Conversation

Speculation about Johnson's physique often bundles testosterone with recombinant human growth hormone. These are distinct compounds with distinct regulatory frameworks and distinct evidence bases.

FDA-Approved Indications for rhGH in Adults

The FDA approves recombinant human growth hormone in adults for adult-onset growth hormone deficiency (AGHD), HIV-associated wasting, and short bowel syndrome, among a small number of other indications. The FDA's list of approved somatropin products is searchable via Drugs@FDA. Prescribing rhGH for physique enhancement or anti-aging is off-label and not supported by the evidence base for healthy adults.

What the Evidence Shows for Healthy Adults

A 2007 meta-analysis by Liu et al. In the Annals of Internal Medicine examined 27 randomized controlled trials of rhGH in healthy older adults. Mean lean body mass increased by 2.1 kg and fat mass decreased by 2.4 kg, but functional outcomes including strength and exercise capacity showed no significant improvement, and adverse effects (edema, arthralgias, carpal tunnel syndrome, glucose intolerance) were common. The Liu et al. Meta-analysis is available on PubMed.

That finding is clinically useful: patients who believe rhGH produces dramatic physique changes in healthy adults are working from incomplete information.

The Legal Framework

The Human Growth Hormone Restrictions Act of 1990, codified in 21 U.S.C. § 333(f), made off-label distribution of HGH a federal felony, carrying up to five years in prison per offense. This is a point worth raising clearly when patients ask about obtaining growth hormone outside a clinical setting.

The "Celebrity Effect" on TRT Prescribing Requests

Celebrity visibility around TRT and hormonal therapies has measurable effects on patient behavior. A 2021 cross-sectional survey published in JAMA Internal Medicine found that direct-to-consumer advertising and media exposure were independently associated with increased testosterone testing requests, even among men with no symptoms of hypogonadism. See the JAMA Internal Medicine reference on PubMed.

Johnson occupies a specific cultural position: a figure who is both aspirational and unusually transparent about personal health topics. His openness about mental health, diet, and training regimens makes him a credible source in the eyes of many patients, even on topics where his public record is incomplete.

The Misattribution Problem

Patients frequently attribute a celebrity's physique entirely to a single compound, whether that is testosterone, HGH, or a GLP-1 receptor agonist. In practice, elite physiques at the professional or near-professional level reflect decades of resistance training, highly structured nutrition, professional recovery support (sleep teams, physical therapists, massage therapists), and genetic advantages, in addition to any pharmacological support. Collapsing all of that into "he takes TRT" removes context that patients need to make rational decisions.

A Clinician Framework for These Conversations

The following four-step framework gives clinicians a structured way to handle "The Rock takes TRT, can I get it?" inquiries without dismissing the patient or over-medicalizing the visit.

Step 1. Acknowledge the question without judgment. The patient came to a clinician rather than ordering from an unregulated online source. That is the right behavior and worth affirming.

Step 2. Separate confirmed fact from inference. Walk through what Johnson has actually said versus what is media inference. Patients often appreciate the distinction once it is drawn clearly.

Step 3. Pivot to the patient's own symptoms. Ask directly: "Are you experiencing any symptoms that concern you, such as fatigue, reduced sex drive, or difficulty building muscle despite consistent training?" This moves the conversation to a diagnostic frame.

Step 4. Order appropriately or explain why you are not ordering. If symptoms are present, two morning total testosterone values, LH, FSH, prolactin, and a metabolic panel are a reasonable starting workup. If symptoms are absent, explain the AUA 2018 criteria and document the conversation.

What Supraphysiologic Testosterone Actually Does to the Body

Some patients assume that more testosterone always means better outcomes. The pharmacology does not support that assumption.

Cardiovascular Risk

The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, enrolled men aged 45 to 80 with hypogonadism and elevated cardiovascular risk or established cardiovascular disease. Testosterone replacement did not significantly increase the rate of major adverse cardiovascular events (MACE) compared to placebo over a median follow-up of 33 months. The TRAVERSE trial is available at NEJM. The trial studied therapeutic doses, not supraphysiologic bodybuilding doses. Supraphysiologic testosterone is associated with left ventricular hypertrophy, dyslipidemia (HDL suppression), and increased hematocrit, all of which raise cardiovascular risk in ways the TRAVERSE design did not test.

Fertility Suppression

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal (HPG) axis, reducing LH and FSH secretion and consequently dropping intratesticular testosterone and spermatogenesis. Men who want to preserve fertility should not use standard TRT formulations. Alternatives include clomiphene citrate (off-label, 25 to 50 mg every other day) or human chorionic gonadotropin (hCG), both of which stimulate endogenous testosterone production without suppressing the HPG axis. The American Society for Reproductive Medicine has published guidance on fertility preservation in men undergoing hormonal therapy. See ASRM resources at asrm.org.

Polycythemia

Testosterone stimulates erythropoietin production. Hematocrit values above 54 percent require dose reduction or temporary cessation of TRT, per the Endocrine Society 2018 guideline. Polycythemia raises thrombotic risk, including deep vein thrombosis and pulmonary embolism. This is not a theoretical concern; it is one of the most common clinically significant adverse effects of TRT.

Testicular Atrophy and Endogenous Suppression

Long-term exogenous testosterone, especially at supraphysiologic doses, causes testicular atrophy that may be only partially reversible after cessation. Post-cycle recovery of the HPG axis can take 6 to 24 months, and in some cases, permanent hypogonadism results.

Putting the Physique in Context: What Training and Nutrition Actually Do

Johnson has trained under professional supervision for decades. His documented daily caloric intake, widely reported in his own social media posts, has at various points exceeded 5,000 to 6,000 kilocalories per day, structured around high-protein meals (reportedly 2.3 to 3.1 g protein per kg bodyweight). Progressive overload resistance training, practiced consistently for 30-plus years, drives muscle protein synthesis through androgen receptor upregulation and satellite cell activation, independent of exogenous hormone use.

A 2017 systematic review in the British Journal of Sports Medicine by Morton et al. (N=1,105 participants across 49 studies) found that dietary protein supplementation significantly increased muscle mass during resistance training, with gains plateauing at approximately 1.62 g/kg/day in most populations. The Morton et al. Review is on PubMed.

Patients benefit from understanding that the training stimulus, nutritional architecture, sleep quality, and genetic predisposition underpinning a physique like Johnson's are not replicable by TRT alone, regardless of dose.

Direct-to-Consumer TRT Clinics: What Patients May Already Be Using

The rise of direct-to-consumer telehealth testosterone prescribing means many patients asking about "The Rock's TRT" may already have accessed testosterone through an online clinic before the conversation happens. Platforms operating in this space have faced regulatory scrutiny. The FDA issued warning letters in 2023 to compounding pharmacies supplying testosterone for non-FDA-approved indications. See FDA enforcement actions at fda.gov.

Clinicians should ask about current supplement and medication use without assumption, since patients may not volunteer that they are already on testosterone from another provider. A serum testosterone drawn without this context can be misleading.

Key Guideline Quotations

The AUA 2018 guideline states: "Clinicians should use a total testosterone level below 300 ng/dL as a threshold for diagnosing testosterone deficiency." This threshold exists precisely to prevent diagnostic overreach driven by nonspecific symptoms or patient preference alone.

The Endocrine Society 2018 guideline states: "We suggest against starting testosterone therapy in patients who are planning fertility in the near term." This is a direct contraindication that celebrity-driven requests may cause patients to overlook entirely.

A Note on Physician Responsibility in the Celebrity-Influence Era

The American Academy of Family Physicians and multiple endocrinology societies have issued statements cautioning against prescribing testosterone for age-related physiologic decline in the absence of documented hypogonadism. See AAFP position resources at aafp.org. The pressure clinicians face, from patients who arrive citing celebrity examples, is real. Documenting the diagnostic rationale for any TRT prescription, and documenting the conversation when a request is declined, is sound medico-legal practice regardless of the source of the patient's inquiry.